Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy

Eye (Basingstoke)

Volumn 27, Issue 3, 2013, Pages 353-362

  Lim, S H ^a   Chang, W ^a   Sagong, M ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

choroidal hyperpermeability; chronic central serous chorioretinopathy; indocyanine green angiography; photodynamic therapy

Indexed keywords

ADULT; AGED; ARTICLE; CENTRAL SEROUS RETINOPATHY; CHOROID CAPILLARY LAYER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; FEMALE; FLUORESCENCE; HALF FLUENCE PHOTODYNAMIC THERAPY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; MALE; MEMBRANE PERMEABILITY; OBSERVATIONAL STUDY; PHOTODYNAMIC THERAPY; PROSPECTIVE STUDY; RECURRENCE RISK; RECURRENT DISEASE; SUBRETINAL FLUID; VISUAL ACUITY;

EID: 84875171548     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2013.13     Document Type: Article

References (29)

1. Piccolino FC, Borgia L, Zinicola E, Zingirian M. Indocyanine green angiographic findings in central serous chorioretinopathy. Eye 1995; 9: 324-332.
2. Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996; 103: 2070-2079; (discussion 2079-2080).
3. Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: An update on pathogenesis and treatment. Eye 2010; 24: 1743-1756.
4. Spitznas M. Pathogenesis of central serous retinopathy: A new working hypothesis. Graefes Arch Clin Exp Ophthalmol 1986; 224: 321-324. (Pubitemid 16113162)
5. Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996; 16: 203-213. (Pubitemid 26190849)
6. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996; 121: 26-34. (Pubitemid 26026078)
7. Jalkh AE, Jabbour N, Avila MP, Trempe CL, Schepens CL. Retinal pigment epithelium decompensation. I. Clinical features and natural course. Ophthalmology 1984; 91: 1544-1548. (Pubitemid 15197029)
8. Ie D, Yannuzzi LA, Spaide RF, Rabb MF, Blair NP, Daily MJ. Subretinal exudative deposits in central serous chorioretinopathy. Br J Ophthalmol 1993; 77: 349-353. (Pubitemid 23193380)
9. Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA, Negrao S. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 2003; 23: 1-7; (quiz 137-138). (Pubitemid 36348476)
10. Ficker L, Vafidis G, While A, Leaver P. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1988; 72: 829-834. (Pubitemid 18265841)
11. Piccolino FC. Laser treatment of eccentric leaks in central serous chorioretinopathy resulting in disappearance of untreated juxtafoveal leaks. Retina 1992; 12: 96-102.
12. Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2010; 30: 100-106.
13. Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 2009; 19: 613-617.
14. Huang WC, Chen WL, Tsai YY, Chiang CC, Lin JM. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eye 2009; 23: 488-489.
15. Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003; 23: 752-763. (Pubitemid 38040573)
16. Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: A novel treatment at the primary disease level. Br J Ophthalmol 2003; 87: 1453-1458. (Pubitemid 38010546)
17. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: A pilot study. Retina 2003; 23: 288-298. (Pubitemid 36792972)
18. Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: A nonrandomized clinical trial. Am J Ophthalmol 2010; 149: 307-315.
19. Nicolo M, Zoli D, Musolino M, Traverso CE. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol 2012; 153: 474-480.
20. Inoue R, Sawa M, Tsujikawa M, Gomi F. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol 2010; 149: 441-446.
21. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trialsYTAP report. Arch Ophthalmol 1999; 117: 1329-1345.
22. Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006; 47: 371-376. (Pubitemid 46780838)
23. Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002; 240: 748-757. (Pubitemid 36104156)
24. Maruko I, Iida T, Sugano Y, Ojima A, Sekiryu T. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina 2011; 31: 1603-1608.
25. Kim KS, Lee WK. Photodynamic therapy with verteporfin for avascular serous pigment epithelial detachment in elderly Koreans. Retina 2010; 30: 93-99.
26. Negi A, Marmor MF. Experimental serous retinal detachment and focal pigment epithelial damage. Arch Ophthalmol 1984; 102: 445-449. (Pubitemid 14197300)
27. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, Viestenz A, Naumann GO. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002; 120: 835-844. (Pubitemid 34620368)
28. Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 2008; 28: 85-93.
29. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularizationYverteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-560.